Preclinical
The battle against COVID-19 rages on, and other therapeutics are making their way through the clinic, including monoclonal antibody treatments and antivirals. BioSpace takes a look at some of the ongoing efforts to stem the rate of infection from the virus.
Ohio-based Forge Biologics secured $120 million in a Series B financing round to support the clinical development of its gene therapy program for rare diseases, including the typically fatal Krabbe disease.
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
Top-line results from the Phase III INVIGORATE trial show Aldeyra Therapeutics’, reproxalap, significantly reduced ocular itching in patients with allergic conjunctivitis.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
There is hope for uniQure’s HOPE-B trial after all. Shares of uniQure NV are climbing this morning after the company announced the clinical hold on its hemophilia B gene therapy has been lifted by the U.S. Food and Drug Administration.
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
PRESS RELEASES